Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27622582 | 0.89 | L3MBTL1 (0.59) | NPC1RAB9AMAPTL3MBTL1NR4A1 | |
| SCHEMBL1025697 | 0.88 | MAPT (0.56) | NPC1RAB9AMAPTL3MBTL1TP53 | |
| SCHEMBL27683875 | 0.80 | NPC1 (0.49) | NPC1RAB9AMAPTALBALDH1A1 | |
| SCHEMBL27707508 | 0.77 | ALB (0.44) | NPC1MAPTALBTP53TSHR | |
| SCHEMBL2571844 | 0.75 | L3MBTL1 (0.62) | NPC1RAB9AMAPTL3MBTL1NR4A1 | |
| SCHEMBL4551433 | 0.75 | NR4A1 (0.62) | NPC1RAB9ANR4A1ALBTSHR | |
| SCHEMBL29583954 | 0.75 | NR4A1 (0.62) | NPC1RAB9ANR4A1ALBTSHR | |
| SCHEMBL27707489 | 0.74 | CA12 (0.47) | NPC1RAB9AL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL14815032 | 0.74 | MAPT (0.56) | NPC1RAB9AMAPTTP53TSHR | |
| SCHEMBL16429101 | 0.73 | ALB (0.59) | NPC1NR4A1ALBTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675694-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2017-06-13 | — | — | US | disclosed |
| US-9675694-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2017-06-13 | — | — | US | disclosed |
| US-9675694-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2017-06-13 | — | — | US | disclosed |
| CN-101583614-B | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENT MANAGEMENT | 2014-01-22 | — | — | CN | disclosed |
| US-20140004111-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2014-01-02 | — | — | US | disclosed |
| US-8598194-B2 | Polycyclic agents for the treatment of respiratory syncytial virus infections | BIOTA SCIENTIFIC MANAGEMENT PTY LTD. (AU) | 2013-12-03 | — | — | US | disclosed |
| EP-2069353-B1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2011-11-09 | — | — | EP | disclosed |
| EP-2069353-B1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENT MANAGEMENT (AU) | 2011-11-09 | — | — | EP | disclosed |
| US-20100021458-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20100021458-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-01-28 | — | — | US | disclosed |
| US-20100021458-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-01-28 | — | — | US | disclosed |
| WO-2008037011-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004111-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | MAVS, ZC3HAV1, POLI | NPC1 850/4885RAB9A 3331/4885MAPT 4649/4885 |
| US-20100021458-A1 | POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS | MAVS, ZC3HAV1, POLI | NPC1 850/4885RAB9A 3331/4885MAPT 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.